Frontlight ResearchEarly access
CompletedPhase 2
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
Key facts
- Who runs it
- Beijing InnoCare Pharma Tech Co., Ltd.
- Where
- China16 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 47 people enrolled
- Started
- 10 Aug 2019
- Ended
- 9 Jan 2024
- Type of study
- Interventional
- Treatments tested
- ICP-022
- Record updated
- 18 April 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Clinical and histologically confirmed giant globulinemia Fahrenheit (WM Ii International Working Group Standards, IWWM-2, 2003) (Owen et al., 2003)
- At least one treatment indication is met (7th WM International Working Group standards, IWWM-7) (Dimopoulos et al., 2014)
- With the lowest serum IgM value >2 times ULN as the efficacy evaluation index
- ECOG physical strength score 0-2
- Voluntary written informed consent prior to trial screening
Who cannot take part
- Patients who had received autologous stem cell transplantation within the previous 6 months
- Present or prior history of other malignant neoplasms, unless radical treatment has been performed and there is no evidence of recurrence or metastasis in the last 5 years
- Demonstrate disease transformation
- A history of organ transplantation or allogeneic bone marrow transplantation; NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
- Amyloidosis and central nervous system (CNS) involvement caused by WM
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.
Read full original descriptionShow less
Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R WM will be evaluated in approximately 44 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.
The group in the trial
- ICP-022Treatment being tested
Subjects will take ICP-022 150mg once daily (QD).
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Open Clinical Trial to Evaluate the Safety and Efficacy of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia (WM)
- Publications
- Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.Advances in hematology, 2024
- Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study.EClinicalMedicine, 2022
- Record updated
- 18 April 2024